Carolyn Tang - Mar 8, 2022 Form 4 Insider Report for Arcus Biosciences, Inc. (RCUS)

Role
General Counsel
Signature
/s/ Carolyn Tang, Attorney-in-Fact
Stock symbol
RCUS
Transactions as of
Mar 8, 2022
Transactions value $
$0
Form type
4
Date filed
3/10/2022, 04:09 PM
Previous filing
Dec 20, 2021
Next filing
Jun 21, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RCUS Common Stock Award $0 +16.3K +92.52% $0.00 33.8K Mar 8, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RCUS Stock Option (right to buy) Award $0 +65K $0.00 65K Mar 8, 2022 Common Stock 65K $33.03 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2022, subject to the Reporting Person's continued service to the Company.
F2 The option is exercisable in 48 equal monthly installments after January 1, 2022, subject to the Reporting Person's continued service to the Company.